Things getting busy. Another filing.
Things getting busier - just completed a reverse merger with Retrophin- ticker changed to RTRX. Looks like their lead compound is for FSGS. Idk anything about kidney disease, what is that space like?
Check out the 8-K. Also, shkreli just killed it on his ONTY call.
I am not a MD but a savy investor has to look at the upside of the orphan space. Very high PPPY and quick trials. This thing could be off to the races.